Clinical Trial Update: Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

An early-phase clinical study evaluating a BCMA-targeted CAR T-cell therapy for relapsed/refractory multiple myeloma; the trial status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA-targeted CAR T-Cell Injection

Snippet

Sponsor: Chulalongkorn University | Conditions: Relapsed/Refractory Multiple Myeloma (MM) | EARLY_Phase 1 | Status: NOT_YET_RECRUITING